Literature DB >> 20404727

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

Jason E Faris1, Matthew R Smith.   

Abstract

PURPOSE OF REVIEW: To summarize the metabolic alterations associated with androgen deprivation therapy (ADT) for prostate cancer and to evaluate the evidence linking ADT with an increased risk of diabetes and cardiovascular disease. RECENT
FINDINGS: ADT by either bilateral orchiectomy or treatment with gonadotropin-releasing hormone agonists causes changes in body composition, alterations in lipid profiles, and decreased insulin sensitivity. The spectrum of metabolic changes during ADT is distinct from classically described metabolic syndrome. Population-based, linked cancer registry studies have consistently reported significant associations between ADT and greater risk for diabetes mellitus. Some but not all studies have reported a link between ADT and cardiovascular disease risk. Most studies have reported no increase in cardiovascular mortality following ADT.
SUMMARY: ADT appears causally associated with diabetes mellitus. ADT is also linked to cardiovascular morbidity, although there is less evidence that this relationship is causal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404727      PMCID: PMC5120548          DOI: 10.1097/MED.0b013e3283391fd1

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  84 in total

1.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

2.  Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

Authors:  Zhao Chen; Michael Maricic; Paul Nguyen; Frederick R Ahmann; Roberta Bruhn; Bruce L Dalkin
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

3.  Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

Authors:  M B Garnick
Journal:  Urology       Date:  1986-01       Impact factor: 2.649

Review 4.  Testosterone, body composition and aging.

Authors:  A Vermeulen; S Goemaere; J M Kaufman
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

5.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

7.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

8.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

9.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

Review 10.  Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.

Authors:  Philip J Saylor; Nancy L Keating; Matthew R Smith
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

View more
  25 in total

1.  ADT and the metabolic syndrome: no good deed goes unpunished.

Authors:  Jehonathan H Pinthus
Journal:  Can Urol Assoc J       Date:  2011-02       Impact factor: 1.862

Review 2.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

3.  Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.

Authors:  Huei-Ting Tsai; Nancy L Keating; Stephen K Van Den Eeden; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Matthew R Smith; Arnold L Potosky
Journal:  J Urol       Date:  2014-12-15       Impact factor: 7.450

4.  Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.

Authors:  Chris Wong; Peggy Chu; Jeremy Teoh; Peter Chiu; C H Yee; Lysander Chau; Marco Chan; Helen Wan; Steven Leung; C F Ng
Journal:  Int Urol Nephrol       Date:  2022-02-25       Impact factor: 2.370

Review 5.  Emerging role of testosterone in pancreatic β-cell function and insulin secretion.

Authors:  Weiwei Xu; Jamie Morford; Franck Mauvais-Jarvis
Journal:  J Endocrinol       Date:  2019-01-01       Impact factor: 4.286

Review 6.  Physical functioning for prostate health.

Authors:  Roanne Segal
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

7.  The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer.

Authors:  Jennifer H Gunter; Amy A Lubik; Ian McKenzie; Michael Pollak; Colleen C Nelson
Journal:  Adv Urol       Date:  2012-04-03

Review 8.  Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes.

Authors:  Christina Wang; Graham Jackson; T Hugh Jones; Alvin M Matsumoto; Ajay Nehra; Michael A Perelman; Ronald S Swerdloff; Abdul Traish; Michael Zitzmann; Glenn Cunningham
Journal:  Diabetes Care       Date:  2011-07       Impact factor: 19.112

Review 9.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

Review 10.  Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review.

Authors:  S Sattar; K R Haase; C Bradley; E Papadopoulos; S Kuster; D Santa Mina; M Tippe; A Kaur; D Campbell; A M Joshua; C Rediger; O Souied; S Alibhai
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-06-09       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.